| Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the … J Barratt, R Lafayette, J Kristensen, A Stone, D Cattran, J Floege, V Tesar, ... Kidney international 103 (2), 391-402, 2023 | 152 | 2023 |
| Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial HJL Heerspink, J Radhakrishnan, CE Alpers, J Barratt, S Bieler, U Diva, ... The Lancet 401 (10388), 1584-1594, 2023 | 124 | 2023 |
| Different design of enzyme-triggered CO-releasing molecules (ET-CORMs) reveals quantitative differences in biological activities in terms of toxicity and inflammation E Stamellou, D Storz, S Botov, E Ntasis, J Wedel, S Sollazzo, BK Krämer, ... Redox biology 2, 739-748, 2014 | 96 | 2014 |
| Iron dienylphosphate tricarbonyl complexes as water-soluble enzyme-triggered CO-releasing molecules (ET-CORMs) S Romanski, H Rücker, E Stamellou, M Guttentag, JM Neudörfl, ... Organometallics 31 (16), 5800-5809, 2012 | 87 | 2012 |
| Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial BH Rovin, J Barratt, HJL Heerspink, CE Alpers, S Bieler, DW Chae, ... The Lancet 402 (10417), 2077-2090, 2023 | 80 | 2023 |
| Enzyme-triggered CO-releasing molecules (ET-CORMs): evaluation of biological activity in relation to their structure S Romanski, E Stamellou, JT Jaraba, D Storz, BK Krämer, M Hafner, ... Free Radical Biology and Medicine 65, 78-88, 2013 | 77 | 2013 |
| Synthesis and Performance of Acyloxy-diene-Fe(CO)3 Complexes with Variable Chain Lengths as Enzyme-Triggered Carbon Monoxide-Releasing Molecules S Botov, E Stamellou, S Romanski, M Guttentag, R Alberto, JM Neudörfl, ... Organometallics 32 (13), 3587-3594, 2013 | 62 | 2013 |
| Atrial fibrillation in chronic hemodialysis patients: prevalence, types, predictors, and treatment practices in Greece G Tsagalis, N Bakirtzi, E Manios, I Chouliaras, P Papagiannidou, ... Artificial organs 35 (10), 916-922, 2011 | 45 | 2011 |
| IgA nephropathy E Stamellou, C Seikrit, SCW Tang, P Boor, V Tesař, J Floege, J Barratt, ... Nature Reviews Disease Primers 9 (1), 67, 2023 | 43 | 2023 |
| Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation E Stamellou, J Floege Nephrology Dialysis Transplantation 33 (10), 1683-1689, 2018 | 39 | 2018 |
| N-Octanoyl dopamine inhibits the expression of a subset of κB regulated genes: potential role of p65 Ser276 phosphorylation MC Hottenrott, J Wedel, S Gaertner, E Stamellou, T Kraaij, L Mandel, ... PLoS One 8 (9), e73122, 2013 | 24 | 2013 |
| Regenerating tubular epithelial cells of the kidney E Stamellou, K Leuchtle, MJ Moeller Nephrology Dialysis Transplantation 36 (11), 1968-1975, 2021 | 22 | 2021 |
| N-octanoyl dopamine treatment of endothelial cells induces the unfolded protein response and results in hypometabolism and tolerance to hypothermia E Stamellou, J Fontana, J Wedel, E Ntasis, C Sticht, A Becker, P Pallavi, ... PLoS One 9 (6), e99298, 2014 | 14 | 2014 |
| N-Octanoyl dopamine transiently inhibits T cell proliferation via G1 cell-cycle arrest and inhibition of redox-dependent transcription factors J Wedel, MC Hottenrott, E Stamellou, A Breedijk, C Tsagogiorgas, ... Journal of Leukocyte Biology 96 (3), 453-462, 2014 | 12 | 2014 |
| TESTING the effects of corticosteroids in patients with IgA nephropathy C Seikrit, E Stamellou, T Rauen, J Floege Nephrology Dialysis Transplantation 37 (10), 1786-1788, 2022 | 11 | 2022 |
| Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential … P Pallavi, M Pretze, J Caballero, Y Li, BB Hofmann, E Stamellou, S Klotz, ... Journal of Medicinal Chemistry 61 (7), 3126-3137, 2018 | 11 | 2018 |
| Intestinal permeability in patients with IgA nephropathy and other glomerular diseases: an observational study C Seikrit, JI Schimpf, S Wied, E Stamellou, A Izcue, O Pabst, T Rauen, ... Journal of Nephrology 36 (2), 463-474, 2023 | 10 | 2023 |
| Precision medicine in immunoglobulin A nephropathy: still a journey ahead C Seikrit, T Rauen, E Stamellou, J Floege Nephrology Dialysis Transplantation 36 (Supplement_2), 24-30, 2021 | 9 | 2021 |
| N-acyl dopamine derivates as lead compound for implementation in transplantation medicine J Wedel, P Pallavi, E Stamellou, BA Yard Transplantation reviews 29 (3), 109-113, 2015 | 8 | 2015 |
| Dopamine treatment of brain-dead Fisher rats improves renal histology but not early renal function in Lewis recipients after prolonged static cold storage J Fontana, B Yard, E Stamellou, H Wenz, U Benck, P Schnuelle, S Hoeger Transplantation Proceedings 46 (10), 3319-3325, 2014 | 8 | 2014 |
